Bharathi Upadhya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1049488/publications.pdf

Version: 2024-02-01

64 papers

1,532 citations

430754 18 h-index 330025 37 g-index

64 all docs

64
docs citations

64 times ranked 2092 citing authors

#	Article	IF	CITATIONS
1	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. New England Journal of Medicine, 2021, 385, 203-216.	13.9	267
2	Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005254.	1.6	129
3	Heart failure with preserved ejection fraction in the elderly: scope of the problem. Journal of Molecular and Cellular Cardiology, 2015, 83, 73-87.	0.9	113
4	Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 640-649.	1.9	101
5	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circulation: Heart Failure, 2017, 10, .	1.6	88
6	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology, 2020, 43, 145-155.	0.7	83
7	Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. Journal of Geriatric Cardiology, 2015, 12, 294-304.	0.2	68
8	Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2017, 65, 2431-2440.	1.3	61
9	Frailty Among Older Decompensated HeartÂFailure Patients. JACC: Heart Failure, 2019, 7, 1079-1088.	1.9	61
10	Sarcopenic Obesity and the Pathogenesis of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2015, 12, 205-214.	1.3	56
11	Heart Failure with Preserved Ejection Fraction in Older Adults. Heart Failure Clinics, 2017, 13, 485-502.	1.0	50
12	Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2017, 65, 2374-2382.	1.3	36
13	Rehabilitation Intervention in Older Patients With Acute HeartÂFailure WithÂPreserved Versus Reduced EjectionÂFraction. JACC: Heart Failure, 2021, 9, 747-757.	1.9	32
14	What the Dead Can Teach the Living. Circulation, 2015, 131, 522-524.	1.6	30
15	Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Failure Reviews, 2018, 23, 609-629.	1.7	29
16	Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 457-459.	1.2	28
17	Prolongation of <scp>QT</scp> c intervals and risk of death among patients with sickle cell disease. European Journal of Haematology, 2013, 91, 170-178.	1.1	26
18	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. Hypertension, 2019, 74, 276-284.	1.3	26

#	Article	IF	Citations
19	Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART. Hypertension, 2021, 77, 1571-1580.	1.3	17
20	Right Ventricular Morphology and Systolic Function in Left Ventricular Noncompaction Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1018-1023.	0.7	15
21	Is Left Ventricular Hypertrophy a Valid Therapeutic Target?. Current Hypertension Reports, 2019, 21, 47.	1.5	15
22	Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2020, 22, 82.	1.5	13
23	Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. Journal of Cardiac Failure, 2004, 10, 31-35.	0.7	12
24	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. American Journal of Cardiovascular Drugs, 2017, 17, 283-298.	1.0	10
25	Preprocedural White Blood Cell Count and Major Adverse Cardiac Events Late After Percutaneous Coronary Intervention in Saphenous Vein Grafts. American Journal of Cardiology, 2005, 96, 515-518.	0.7	9
26	Role of Diastolic Function in Preserved Exercise Capacity in Patients with Reduced Ejection Fractions. Journal of the American Society of Echocardiography, 2015, 28, 1184-1193.	1.2	9
27	Association of P-Wave Axis With Incident Atrial Fibrillation in Diabetes Mellitus (from the ACCORD) Tj ETQq $1\ 1$	0.784314	rgBJ /Overloc
28	Associations between physical activity, sedentary behaviour and left ventricular structure and function from the Echocardiographic Study of Latinos (ECHO-SOL). Open Heart, 2021, 8, e001647.	0.9	9
29	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008322.	1.6	9
30	Delay of left ventricular longitudinal expansion with diastolic dysfunction: impact on load dependence of e′ and longitudinal strain rate. Physiological Reports, 2014, 2, e12082.	0.7	8
31	Left ventricular diastolic dysfunction and exercise intolerance in obese heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1535-H1542.	1.5	8
32	Relation of Cannabis Use to Elevated Atherosclerotic Cardiovascular Disease Risk Score. American Journal of Cardiology, 2022, 165, 46-50.	0.7	8
33	HeartÂFailure Prevention in Older Patients Using Intensive Blood Pressure Reduction. JACC: Heart Failure, 2019, 7, 1032-1041.	1.9	7
34	Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney?. Journal of Cardiac Failure, 2020, 26, 108-111.	0.7	6
35	Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention. Journal of Invasive Cardiology, 2005, 17, 243-7.	0.4	6
36	Skeletal muscle abnormalities in heart failure with preserved ejection fraction. Heart Failure Reviews, 2023, 28, 157-168.	1.7	6

#	Article	IF	CITATIONS
37	Papillary fibroelastoma of the mitral valve chordae with systemic embolization. Journal of Cardiology Cases, 2014, 10, 125-128.	0.2	5
38	New Concepts in an Old Disease. JACC: Cardiovascular Imaging, 2017, 10, 634-636.	2.3	5
39	The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. American Heart Journal, 2018, 201, 164-167.	1.2	5
40	Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?. Current Hypertension Reports, 2019, 21, 9.	1.5	5
41	Wake Forest University longâ€ŧerm followâ€up of type 2 myocardial infarction: The Wakeâ€Up T2MI Registry. Clinical Cardiology, 2019, 42, 592-604.	0.7	5
42	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. Hypertension, 2021, 77, 1804-1814.	1.3	5
43	Exercise training for prevention and treatment of older adults with heart failure with preserved ejection fraction. Experimental Gerontology, 2021, 155, 111559.	1.2	5
44	Left Atrial Stiffness Index Independently Predicts Exercise Intolerance and Quality of Life in Older, Obese Patients With Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 567-575.	0.7	5
45	Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current Hypertension Reports, 2022, 24, 1-20.	1.5	5
46	Cannabis use is associated with prevalent coronary artery disease. American Journal of the Medical Sciences, 2022, 364, 304-308.	0.4	5
47	Cardiothoracic Morphology Measures in Heart Failure Patients to Inform Device Designs. Cardiovascular Engineering and Technology, 2019, 10, 543-552.	0.7	4
48	Exposure to secondhand smoke is associated with increased left ventricular mass. Tobacco Induced Diseases, 2021, 19, 1-7.	0.3	4
49	Cannabis Use and Electrocardiographic Myocardial Injury. American Journal of Cardiology, 2021, 151, 100-104.	0.7	3
50	Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time Has Gone?. Journal of Cardiac Failure, 2020, 26, 283-284.	0.7	2
51	P-wave axis is associated with all-cause mortality in diabetes: The ACCORD trial. Journal of Electrocardiology, 2020, 60, 184-187.	0.4	2
52	Clinical Outcomes in Different Types of Aortic Stenosis as Assessed by Doppler Echocardiography. Journal of Heart Valve Disease, 2016, 25, 672-678.	0.5	2
53	Paint by Numbers. Journal of the American Geriatrics Society, 2019, 67, 7-8.	1.3	1
54	Anticoagulation for coexisting bioprosthetic aortic valve thrombosis and anticoagulantâ€related bleeding: "A double edge swordâ€r Echocardiography, 2020, 37, 1687-1690.	0.3	1

#	Article	IF	Citations
55	Measured Versus Estimated Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007962.	1.6	1
56	Interatrial Stent to Treat Stiff Left Atrium Syndrome. Cardiovascular Revascularization Medicine, 2022, 40, 337-340.	0.3	1
57	Cannabis Use Is Associated with Prevalent Angina in Individuals with Diabetes. Cannabis and Cannabinoid Research, 0, , .	1.5	1
58	Falls, Subclinical Cardiovascular Disease, and a Nonagenarian's Sage Advice. Journal of the American Geriatrics Society, 2019, 67, 1774-1776.	1.3	0
59	Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 1029-1031.	1.9	0
60	Diagnosis of Persistent Left Superior Vena Cava: Lessons Learned from a Recurrent Stroke Case. Case, 2020, 4, 320-323.	0.1	0
61	A Biomarker Approach to UnderstandingÂHFpEF. Journal of the American College of Cardiology, 2020, 75, 1296-1298.	1.2	0
62	Abstract P122: P-wave Axis is Associated With All-Cause Mortality in Diabetes: The ACCORD Trial. Circulation, 2020, 141, .	1.6	0
63	Abstract 15034: Exposure to Secondhand Smoke is Associated With Increased Left Ventricular Mass. Circulation, 2020, 142, .	1.6	0
64	MO094: Intensive Blood Pressure Lowering and Myocardial Fibrosis Biomarkers in Individuals With and Without CKD: Results From the Systolic Blood Pressure Intervention Trial (Sprint). Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0